April 27, 2020
TLC
Archived Files
We believe TLC can achieve a market cap of ~400mm this year based on positive TLC590 Ph2 data, and growing investor enthusiam towards the completion of the TLC599 Ph3 study. […]
January 16, 2020
January 16, 2020 Update
Coverage Updates
Over the past 3-months we have initiated coverage on three companies; Xenon Pharmaceuticals (Nasdaq: XENE), ESSA Pharma (Nasdaq: EPIX), and Acasti Pharma (Nasdaq: ACST). After we issue our initiation reports, […]
November 25, 2019
Acasti Pharma
Archived Files
We are initiating on Acasti Pharma as a high risk investment ideas. Read More.
October 16, 2019
Xenon Pharma
Coverage Universe
We believe through clinical success with their lead assets, XEN496 and XEN1101, Xenon can achieve a market cap of >$1 billion by 2021, reflecting a nearly 4.5x multiple from its […]